NCT06730672
An Exploratory Study on the Failure of Immunotherapy With Vorolanib Combined With Everolimus
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Start date changed from estimate of Dec 30, 2024 to Dec 30, 2025 Show 5 more changesShow less
- Eligibility criteria expanded, about 10 words
- Interventions modified
- Secondary endpoints: details revised at 1 of 5 entries
- Site details revised at 1 of 2 sites
- Study title revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 2
- Start date: Dec 10, 2024 to Dec 30, 2024
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Progression-free survival
Timeframe: From date of initiate treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months until disease progression or death
Secondary (5)
Overall survival
Objective response rate
Disease control rate
Duration of response
Dynamic changes in ctDNA levels and alterations in the ctDNA mutation profile
Arms and interventions
Volonib combined with Everolimus FormationExperimental
Volonib 200mg once daily and Everolimus 5mg once daily
Drugs: Vorolanib combined with Everolimus Formation
Sites
2 sites in 1 country